Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: A consensus report and guide for analysts

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Jit, Mark ^a,b   Levin, Carol ^c   Brisson, Marc ^d,e   Levin, Ann ^f   Resch, Stephen ^g   Berkhof, Johannes ^h   Kim, Jane ^g   Hutubessy, Raymond ⁱ  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c PATH   (United States)

^d Université Laval   (Canada)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Independent Consultant   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

economic evaluation.; Human papillomavirus; low and middle income countries; vaccination

Indexed keywords

CONSENSUS; ECONOMIC ASPECT; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INCOME; LETTER; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; VACCINATION; WART VIRUS; WORLD HEALTH ORGANIZATION;

COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84873019325     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-23     Document Type: Letter

References (35)

1. World Health Organization Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009, 84:118-131. World Health Organization.
2. Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach J. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med 2011, 9:55. 10.1186/1741-7015-9-55, 3117725, 21569407.
3. Yothasamut J, Tantivess S, Teerawattananon Y. Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable?. Value Health 2009, 12(Suppl 3):S26-S30.
4. Andrus JK, Toscano CM, Lewis M, Oliveira L, Ropero AM, Davila M, Fitzsimmons JW. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Rep 2007, 122:811-816. 1997250, 18051674.
5. Iglesias CP, Drummond MF, Rovira J. Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. Int J Technol Assess Health Care 2005, 21:1-14.
6. Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med 2011, 9:54. 10.1186/1741-7015-9-54, 3123559, 21569406.
7. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008, 26(Suppl 10):K76-K86. 2769256, 18847560.
8. Brisson M, Van d V, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351. 10.1159/000214924, 19684446.
9. Levin CE, Van Minh H, Odaga J, Sarit Rout S, Nguyen Thi Ngoc D, Menezes L, Mendoza Araujo M, La Montagne DS. Incremental costs of strategies to deliver human papillomavirus vaccine to young adolescent girls in India, Peru, Uganda and Viet Nam. Bull World Health Organ 2012,
10. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26:4080-4093. 10.1016/j.vaccine.2008.04.053, 18550229.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097. 10.1371/journal.pmed.1000097, 2707599, 19621072.
12. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010, 28:2356-2359. 10.1016/j.vaccine.2009.06.035, 19567247.
13. Tracy L, Gaff HD, Burgess C, Sow S, Gravitt PE, Tracy JK. Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali. Clin Infect Dis 2011, 52:641-645. 10.1093/cid/ciq190, 3106240, 21252142.
14. Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics 2011, 29:781-806. 10.2165/11586560-000000000-00000, 21838332.
15. Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis. Vaccine 2009, 27:6060-6079. 10.1016/j.vaccine.2009.07.026, 19647813.
16. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97:1322-1328. 10.1038/sj.bjc.6604023, 2360471, 17923869.
17. Senouci K, Blau J, Nyambat B, Coumba FP, Gautier L, Da Silva A, Favorov MO, Clemens JD, Stoeckel P, Gessner BD. The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) initiative: a country-driven, multi-partner program to support evidence-based decision making. Vaccine 2010, 28(Suppl 1):A26-A30.
18. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health 2007, 10:336-347. 10.1111/j.1524-4733.2007.00187.x, 17888098.
19. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray C. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organisation; 2003. 2003, Geneva, World Health Organisation.
20. Van d V, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010, 28:5473-5484. 10.1016/j.vaccine.2010.05.056, 20573580.
21. Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011, 22:505-515. 10.1097/EDE.0b013e31821d107b, 21540743.
22. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775. 10.1136/bmj.d5775, 3181234, 21951758.
23. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010, 20:213-219. 10.1093/eurpub/ckp141, 19864366.
24. Brisson M, Van d V, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25:5399-5408. 10.1016/j.vaccine.2007.04.086, 17561316.
25. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012,
26. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006, 15:1295-1310. 10.1002/hec.1148, 16941543.
27. Wellings K, Nanchahal K, Macdowall W, McManus S, Erens B, Mercer CH, Johnson AM, Copas AJ, Korovessis C, Fenton KA, et al. Sexual behaviour in Britain: early heterosexual experience. Lancet 2001, 358:1843-1850. 10.1016/S0140-6736(01)06885-4, 11741623.
28. Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJ, Berkhof J, Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 2011, 8:e1001147. 10.1371/journal.pmed.1001147, 3243713, 22205887.
29. Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009, 27:6196-6202. 10.1016/j.vaccine.2009.08.004, 19698807.
30. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290:781-789. 10.1001/jama.290.6.781, 12915431.
31. health-economic Modelling of Prevention STrategies for Hpv-related Diseases in European Countries. Accessed on 29 November 2012., http://cordis.europa.eu/search/index.cfm?fuseaction=proj.document&PJ_RCN=11314364
32. Lasry A, Richter A, Lutscher F. Recommendations for increasing the use of HIV/AIDS resource allocation models. BMC Public Health 2009, 9(Suppl 1):S8. 10.1186/1471-2458-9-S1-S8, 2779510, 19922692.
33. Bilcke J, Beutels P, Brisson M, Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011, 31:675-692. 10.1177/0272989X11409240, 21653805.
34. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999, 18:341-364. 10.1016/S0167-6296(98)00039-3, 10537899.
35. Craig BM, Brisson M, Chesson H, Giuliano AR, Jit M. Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmo, Sweden, May 9-10, 2009. Clin Ther 2010, 32:1546-1564. 10.1016/j.clinthera.2010.06.017, 20728767.